SCHEMBL7066513

SCHEMBL7066513

O=C(O)C1(NS(=O)(=O)c2cccc(C(F)(F)F)c2)CCCCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.58
HTT P42858 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
CA1 P00915 2/20 0.55
CA2 P00918 2/20 0.55
MMP1 P03956 1/20 0.55
MMP2 P08253 1/20 0.55
MMP9 P14780 1/20 0.55
MMP8 P22894 1/20 0.55
MMP13 P45452 1/20 0.55
NPSR1 Q6W5P4 2/20 0.50
MEN1 O00255 1/20 0.50
GAA P10253 1/20 0.50
KMT2A Q03164 1/20 0.50
SLC1A3 P43003 1/20 0.49
SLC1A2 P43004 1/20 0.49
FAAH O00519 1/20 0.47
TRPV1 Q8NER1 1/20 0.47
KAT6A Q92794 1/20 0.46
ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5675304 0.81 USP2 (0.60) USP2HTTSMN1; SMN2CA1CA2
SCHEMBL14676227 0.79 USP2 (0.58) USP2HTTSMN1; SMN2CA1CA2
SCHEMBL6990928 0.78 USP2 (0.55) USP2HTTSMN1; SMN2KAT6AALDH1A1
SCHEMBL7066464 0.77 HTT (0.57) USP2HTTSMN1; SMN2CA1CA2
SCHEMBL14675849 0.76 USP2 (0.55) USP2HTTSMN1; SMN2CA1CA2
SCHEMBL6994772 0.76 USP2 (0.53) USP2HTTSMN1; SMN2KAT6AALDH1A1
SCHEMBL7064055 0.75 USP2 (0.62) USP2HTTSMN1; SMN2MMP1MMP13
SCHEMBL7064374 0.75 MEN1 (0.50) USP2HTTSMN1; SMN2MEN1KMT2A
SCHEMBL7067864 0.75 USP2 (0.49) USP2HTTSMN1; SMN2MMP2NPSR1
SCHEMBL7067073 0.74 USP2 (0.67) USP2HTTSMN1; SMN2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1222176-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-17 EP claimed
WO-2001027091-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2001-04-19 WO claimed
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production THOMPSON LORIN A (US) 2003-07-10 US disclosed
US-6503901-B1 Alzheimer*s disease and Down*s syndrome treatment BRISTOL MYERS SQUIBB PHARMA COMPANY 2003-01-07 US disclosed
EP-1222176-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-17 EP disclosed
EP-1218377-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-03 EP disclosed
WO-2001027091-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2001-04-19 WO disclosed
WO-2001027108-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production APP, APH1A, BACE1 USP2 1089/4885HTT 1221/4885SMN1; SMN2 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.